Zobrazeno 61 - 66
of 66
pro vyhledávání: '"59"'
Autor:
Blümle, Anette1 bluemle@cochrane.de, Meerpohl, Joerg J.1, Schumacher, Martin1, von Elm, Erik2
Publikováno v:
PLoS ONE. Feb2014, Vol. 9 Issue 2, p1-9. 9p.
Autor:
Calingacion, Mariafe1,2,3, Laborte, Alice1, Nelson, Andrew1, Resurreccion, Adoracion1,3, Concepcion, Jeanaflor Crystal1,3, Daygon, Venea Dara1,3, Mumm, Roland4,5, Reinke, Russell3,6, Dipti, Sharifa3,7, Bassinello, Priscila Zaczuk3,8, Manful, John3,9, Sophany, Sakhan3,10, Lara, Karla Cordero3,11, Bao, Jinsong3,12, Xie, Lihong3,13, Loaiza, Katerine3,14, El-hissewy, Ahmad3,15, Gayin, Joseph3,16, Sharma, Neerja3,17, Rajeswari, Sivakami3,18
Publikováno v:
PLoS ONE. Jan2014, Vol. 9 Issue 1, p1-12. 12p.
Autor:
Zhang, Chun-Ting1 ctzhang@tju.edu.cn
Publikováno v:
PLoS ONE. Apr2013, Vol. 8 Issue 4, p1-8. 8p.
Publikováno v:
PLoS ONE. Mar2013, Vol. 8 Issue 3, p1-9. 9p.
Autor:
Abdoul, Hendy1,2,3 hendy.abdoul@rdb.aphp.fr, Perrey, Christophe1,3,4, Amiel, Philippe4, Tubach, Florence2,5, Gottot, Serge1,2,3, Durand.-Zaleski, Isabelle6, Alberti, Corinne1,2,3, Gagnier, Joel Joseph7
Publikováno v:
PLoS ONE. Sep2012, Vol. 7 Issue 9, Special section p1-15. 15p.
Autor:
Joel Lexchin
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0240966 (2020)
PLoS ONE
PLoS ONE
IntroductionStudies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted